Patent ID: 11866444
Assignee: LIXTE BIOTECHNOLOGY, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for in vivo delivery of endothall to a cancer cell in a subject afflicted with cancer, the method comprising administering to the subject a compound having the structure:, or a pharmaceutically acceptable salt thereof,
wherein the delivery of endothall to the cancer cell in the subject is effective to treat the cancer, and
wherein the cancer is brain cancer, breast cancer, colon cancer, large cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promylocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, colorectal cancer, ovarian cancer, lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma cell, adrenocortical cancer, bladder cancer, osteosarcoma, cervical cancer, esophageal, gallbladder, head and neck cancer, renal cancer, melanoma, pancreatic cancer, rectal cancer, thyroid cancer, throat cancer, prostate cancer, lung cancer, or hepatocellular carcinoma.